FITC Annexin V

Pricing & Availability
Regulatory Status
RUO
Other Names
Annexin A5
Ave. Rating
Submit a Review
Product Citations
publications
AnnexinV_FITC_092908.jpg
Human T leukemia cell line, Jurkat, non-treated (top) or treated (bottom) with BioLegend’s anti-human CD95 (EOS9.1) mAb (cat. 305704) for 6 hours, then stained with Annexin V-FITC and Propidium Iodide (PI) (cat. 421301)
  • AnnexinV_FITC_092908.jpg
    Human T leukemia cell line, Jurkat, non-treated (top) or treated (bottom) with BioLegend’s anti-human CD95 (EOS9.1) mAb (cat. 305704) for 6 hours, then stained with Annexin V-FITC and Propidium Iodide (PI) (cat. 421301)
  • B_AnnexinV_FITC_092908.jpg
See FITC spectral data
Cat # Size Price Quantity Check Availability Save
640905 25 tests 67€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
640906 100 tests 156€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
640945 300 tests 324€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

Annexin V (or Annexin A5) is a member of the annexin family of intracellular proteins that binds to phosphatidylserine (PS) in a calcium-dependent manner. PS is normally only found on the intracellular leaflet of the plasma membrane in healthy cells, but during early apoptosis, membrane asymmetry is lost and PS translocates to the external leaflet. Fluorochrome-labeled Annexin V can then be used to specifically target and identify apoptotic cells. Annexin V Binding Buffer (cat. no. 422201) is recommended for use with Annexin V staining.Annexin V binding alone cannot differentiate between apoptotic cells and necrotic. Therefore, we recommend using our Helix NP™ Blue (Cat. No. 425305), Helix NP™ Green (Cat.  No. 425303) or Helix NP™ NIR (Cat. No. 425301). Early apoptotic cells will exclude 7-AAD and PI, while late stage apoptotic cells and necrotic cells will stain positively, due to the passage of these dyes into the nucleus where they bind to DNA.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Human, Mouse, Rat
Reported Reactivity
Other Species
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA)
Preparation
The purified protein was conjugated with FITC under optimal conditions.
Concentration
Lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling
The Annexin V solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested

Recommended Usage

Each lot of this product is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µl per 100,000 - million cells in a 100 µl volume of Annexin V Binding Buffer (Cat No. 422201). It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Application Notes

Annexin V Staining
1. Wash cells twice with cold BioLegend cell staining buffer (Cat. No. 420201) and then resuspend cells in Annexin V Binding Buffer (Cat. No. 422201) at a concentration of 1x106 cells/mL.
2. Transfer 100 µL of cell suspension in 5 ml test tube.
3. Add 5 µL of FITC Annexin V.
4. Add 10 µL of PI solution (Cat. No. 421301) or 7-AAD (Cat. No. 420403/420404).
5. Gently vortex the cells and incubate for 15 min at RT (25°C) in the dark.
6. Add 400 µL of Annexin V Binding Buffer (Cat. No. 422201) to each tube. Analyze by flow cytometry.


For a better experience detecting apoptosis, we now recommend Apotracker™. Cell staining with Apotracker™ is Calcium independent. Thus, no special buffers are required, and the protocol can be shortened for single-step co-staining with other reagents.

Application References
  1. Koopman G, et al. 1994. Blood 84:1415.
  2. Vermes I, et al. 1995. J. Immunol. Methods 184:39.
  3. Dachary-Prigent J, et al. 1993. Blood 81:2554.
  4. Sekine C, et al. 2009. Int Immunol. PubMed
  5. Grujic M, et al. 2010. J. Immunol. 185:1730. PubMed
  6. Mulik RS, et al. 2010. Int J Pharm. 398:190. PubMed
  7. Gupta A, et al. 2011. Leuk Res. 35:1498. PubMed
  8. Speth C,et al. 2013. J Infect Dis. 207:823. PubMed
  9. Wang Q, et al. 2013. Genes Dev. 27:615. PubMed
  10. Gill K, et al. 2013. Biocheim Biophys Acta. 830:2763. PubMed
  11. Juel HB, et al. 2013. PLoS One. 8:64619. PubMed
  12. Hellmann J, et al. 2013. J. Immunol. 191:1383. PubMed
  13. Sequier S, et al. 2013. PLoS One. 8:70937. PubMed
  14. Galski H, et al. 2013. Biochem Pharmacol. 86:584. PubMed
  15. Chen YL, et al. 2013. J Exp Med. PubMed
  16. Lin WH, et al. 2014. PLoS One. 9:83160. PubMed
  17. Salge-Bartles U, 2014. Thromb res. 133:244. PubMed
  18. Zhang X, et al. 2014. Acta Biochim Biophys Sin. 46:261. PubMed
  19. Intermann J, et al. 2014. Cell Signal. 26:1567. PubMed
  20. de Vires M, 2014. Am J Physiol Lung Cell Mol Physiol. 307:240. PubMed
  21. M Parrula MC, et al. 2014. Virus Res. 189:206. PubMed
  22. Passaro C, et al. 2014. Mol Oncol. 9:78. PubMed
  23. Tsou WI, et al. 2014. J Biol Chem. 289:25750. PubMed
  24. Awojoodu AO, et al. 2014. Blood. 124:1941. PubMed
  25. Xiong R, et al. 2014. Toxicol Appl Pharmacol. 280:285. PubMed
  26. Liu J, et al. 2015. J Mol Cell Cardiol. 80:10. PubMed
Product Citations
  1. Yao Z, et al. 2018. J Virol. 92:00:00. PubMed
  2. Uriostegui–Arcos M, et al. 2020. Open Biol. 10:200050. PubMed
  3. Zhang T, et al. 2022. EBioMedicine. 77:103872. PubMed
  4. Dhoonmoon A, et al. 2022. Nat Commun. 13:5063. PubMed
  5. Zelenka T, et al. 2022. Nat Commun. 13:6954. PubMed
  6. Derudder E, et al. 2016. Proc Natl Acad Sci U S A. 113: 5065-5070. PubMed
  7. Bouhaddou M, et al. 2018. PLoS Comput Biol. 14:e1005985. PubMed
  8. Espinosa-Cueto P, et al. 2017. PLoS One.. 10.1371/journal.pone.0182126. PubMed
  9. Dowling CM, et al. 2021. Sci Adv. 7:. PubMed
  10. Lin YN, et al. 2022. Oncoimmunology. 11:2027136. PubMed
  11. Kim EH, et al. 2020. Elife. 9:00. PubMed
  12. Kitayama J, et al. 2016. PLoS One. 11: 0154542. PubMed
  13. Gedye C, et al. 2016. Sci Rep. 6: 25220. PubMed
  14. Carlsson J, et al. 2015. PLoS One. 10: 0143741. PubMed
  15. Yamauchi T et al. 2018. Cancer cell. 33(3):386-400 . PubMed
  16. Feng W, et al. 2017. Nat Commun. 0.697916667. PubMed
  17. Jones PD, et al. 2018. Arterioscler Thromb Vasc Biol. 38:1711. PubMed
  18. Figueiredo T, et al. 2020. Mol Psychiatry. . PubMed
  19. Lopes-Coelho F, et al. 2021. Front Oncol. 11:656229. PubMed
  20. Wang Q, et al. 2022. Nat Commun. 13:3022. PubMed
  21. Olelewe C, et al. 2022. iScience. 25:104340. PubMed
  22. Gupta A, et al. 2011. Leuk Res. 35:1498. PubMed
  23. Fujii T, et al. 2015. Proc Natl Acad Sci U S A. 112: 12800 - 12805. PubMed
  24. Cardoso B, et al. 2015. PLoS One. 10: 0143897. PubMed
  25. Alcon C, et al. 2020. Cell Death Dis. 0.898611111. PubMed
  26. Bowen ME, et al. 2019. Dev Cell. 50:212. PubMed
  27. Sales–Dias J, et al. 2019. PLoS One. 14:e0217002. PubMed
  28. Santos LC, et al. 2019. Nat Commun. 1.328472222. PubMed
  29. Lim JA, et al. 2018. BMC Cancer. 0.860416667. PubMed
  30. Venter C, et al. 2017. Cell Physiol Biochem. 43:1288. PubMed
  31. Kim Y, et al. 2020. J Neurochem. 155:177. PubMed
  32. Hassan MIA, et al. 2021. Comput Struct Biotechnol J. 19:880. PubMed
  33. Ramalingam P, et al. 2020. J Exp Med. 217:00:00. PubMed
  34. Karavasili C, et al. 2017. International Journal of Pharmaceutics. 10.1016/j.ijpharm.2017.05.061. PubMed
  35. Thompson PJ et al. 2019. Cell metabolism. 29(5):1045-1060 . PubMed
  36. Noguchi F, et al. 2017. Mol Cancer Ther. 1.316666667. PubMed
  37. Kumar S, et al. 2018. Cancers (Basel). 0.724305556. PubMed
  38. Fortin J, et al. 2020. Cancer Cell. 37:308. PubMed
  39. Vereertbrugghen A, et al. 2021. Front Oncol. 11:598319. PubMed
  40. Sun V, et al. 2021. Front Immunol. 12:716661. PubMed
  41. Coray M, et al. 2022. Int J Mol Sci. 23:. PubMed
  42. Soprano M, et al. 2016. PLoS One. 11: 0155970. PubMed
  43. Macpherson L, et al. 2020. Nature. 577:266. PubMed
  44. Chen MS, et al. 2019. Mol Cancer Res. 17:697. PubMed
  45. Ni F, et al. 2019. Cell Stem Cell. 24:608. PubMed
  46. Ning X, et al. 2019. Mol Cell. 74:19. PubMed
  47. Greenblatt SM, et al. 2018. Cancer Cell. 33:1111. PubMed
  48. Naqvi N,et al. 2017. Sci Rep.. 10.1038/s41598-017-12753-1. PubMed
  49. Wang M, et al. 2017. Biochemical and Biophysical Research Communications. 10.1016/j.bbrc.2017.05.097. PubMed
  50. Beeravolu N, McKee C, Chaudhry G 2017. J App Toxicol. 10.1002/jat.3469. PubMed
  51. Kim OV, et al. 2022. iScience. 25:104654. PubMed
  52. Shahzadi SK, et al. 2022. Clin Sci (Lond). 136:181. PubMed
  53. Kolbrink B, et al. 2022. Biochem J. 479:259. PubMed
  54. He C, et al. 2021. Oncoimmunology. 1897295:10. PubMed
  55. Pfalzgraff A, et al. 2016. Sci Rep. 6:31577. PubMed
  56. O'Neill K, et al. 2016. Genes Dev. 30: 973-988. PubMed
  57. Liu J, et al. 2015. J Mol Cell Cardiol. 80:10. PubMed
  58. Vries M, et al. 2014. Am J Physiol Lung Cell Mol Physiol. 307:240. PubMed
  59. Esteghamat F, et al. 2019. Nat Genet. 51:1233. PubMed
  60. Blümel E, et al. 2020. Oncoimmunology. 9:1751561. PubMed
  61. Sekine C, et al. 2009. Int Immunol. 1.079861111. PubMed
  62. Kinsella S, et al. 2021. Cell Rep. 37:109789. PubMed
  63. O'Connor MJ, et al. 2021. Oncogene. 40:4872. PubMed
  64. Parrula M, et al. 2014. Virus Res. 189:206. PubMed
  65. Brigger D, et al. 2015. Cell Death Dis. 6: e1861. PubMed
  66. Zhang J, et al. 2016. Cell Death Dis. 7:e2266. PubMed
  67. Wang D, et al. 2016. J Cell Sci. 129: 2261 - 2272. PubMed
  68. Uchtenhagen H, et al. 2016. Nat Commun. 7:12614. PubMed
  69. Geiger R, et al. 2016. Cell. 167:829-842. PubMed
  70. Rauzan M, et al. 2017. PLoS One. 12:e0174107. PubMed
  71. Liu Y, et al. 2017. Acta Biomater. 10.1016/j.actbio.2017.08.021. PubMed
  72. Chiani M, et al. 2017. Artif Cells Nanomed Biotechnol. 10.1080/21691401.2017.1337029. PubMed
  73. Yang L, et al. 2021. Cell Death Differ. 28:2616. PubMed
  74. Martín Monreal MT, et al. 2021. Front Immunol. 12:716250. PubMed
  75. Schmitz RL, et al. 2021. Cells. 10:. PubMed
  76. Babaei A, et al. 2021. Adv Pharm Bull. 11:361. PubMed
  77. Madala HR, et al. 2020. Cancer Res. 3492:80. PubMed
  78. Clements KE, et al. 2020. Nat Commun. 4.706944444. PubMed
  79. Kamiyama N, et al. 2017. Antiviral Res. 10.1016/j.antiviral.2017.08.007. PubMed
  80. Montero–Herradón S, et al. 2017. Organogenesis. 0.675. PubMed
  81. Nunes SC, et al. 2018. Sci Rep. 6.939583333. PubMed
  82. Sharif T, et al. 2018. Autophagy. 1.101388889. PubMed
  83. Eichelmann AK, et al. 2018. Sci Rep. 8:17553. PubMed
  84. Blümel E, et al. 2019. Oncoimmunology. 8:e1641387. PubMed
  85. Morimoto A, et al. 2021. Nat Commun. 12:2136. PubMed
  86. Norkin M, et al. 2021. Cell Rep. 35:109026. PubMed
  87. Krauss PL, et al. 2021. Front Immunol. 12:730672. PubMed
  88. Zhu Y, et al. 2022. Clin Transl Med. 12:e887. PubMed
  89. Khatib JB, et al. 2022. Oncotarget. 13:1078. PubMed
  90. Salge-Bartels U, et al. 2014. Thromb Res. 133:244. PubMed
  91. Passaro C, et al. 2014. Mol Oncol. 9:78. PubMed
  92. Ligtenberg M, et al. 2016. J Immunol. 196: 759 - 766. PubMed
  93. Hrdinka M, et al. 2016. PLoS One. 11: 0162863. PubMed
  94. Herold N, et al. 2017. Nat Med. 23:256-263. PubMed
  95. Xie S, et al. 2021. Sci Rep. 0.660416667. PubMed
  96. Müller I, et al. 2020. Mol Cell. 970:77. PubMed
  97. Liu H, et al. 2020. Cell Death Dis. 0.767361111. PubMed
  98. Zervou S, et al. 2017. PLoS One.. 10.1371/journal.pone.0182994. PubMed
  99. Ishidome T et al. 2017. EBioMedicine. 22:89-99 . PubMed
  100. Matsuda K, et al. 2021. Cell Rep Methods. 1:100122. PubMed
  101. Vanoli F, et al. 2021. Oncogene. 40:5095. PubMed
  102. Liu H, et al. 2021. J Immunother Cancer. 9:. PubMed
  103. Smith CM, et al. 2021. Biochem J. 478:3331. PubMed
  104. Li Y, et al. 2021. Sci Transl Med. 13:. PubMed
  105. Meyer N, et al. 2021. J Clin Med. 10:. PubMed
  106. Yoon Y, et al. 2016. Stem Cell Reports. 7:840-853. PubMed
  107. Chheda Z, et al. 2016. J Immunol. 197: 2016 - 2026. PubMed
  108. Slone E, et al. 2015. J Leukoc Biol. 98: 791 - 804. PubMed
  109. Séguier S, et al. 2013. PLoS One. 8:70937. PubMed
  110. Litzenburger UM, et al. 2017. Genome Biol. 18:15. PubMed
  111. Rajavel T, et al. 2017. Sci Rep. 2.665277778. PubMed
  112. Grujic M, et al. 2010. J Immunol. 185:1730. PubMed
  113. Gholamrezaei M, et al. 2021. Iran J Parasitol. 15:475. PubMed
  114. Meyer N, et al. 2021. Int J Mol Sci. 22:. PubMed
  115. Kolbrink B, et al. 2022. Cell Mol Life Sci. 79:387. PubMed
  116. Wang Q, et al. 2013. Genes Dev. 27:615. PubMed
  117. Douguet L, et al. 2016. PLoS One. 11:e0166164. PubMed
  118. Toutounchian J, et al. 2016. Mol Pharmacol. 91(1):1-13. PubMed
  119. Pajarillo E, et al. 2020. J Biol Chem. 295:3040. PubMed
  120. Matsumoto A, et al. 2019. J Extracell Vesicles. 9:1696517. PubMed
  121. Pirali T, et al. 2017. ChemMedChem. 1.570833333. PubMed
  122. Ishida M, et al. 2021. Int J Mol Sci. 22:. PubMed
  123. Lee DH, et al. 2020. Circ Res. 127:1182. PubMed
  124. Alsina-Sanchis E, et al. 2020. Mol Cancer Res. . PubMed
  125. L Chang, Y Li, D Kaplan 2016. Sci Rep. 6:36862. PubMed
  126. Becker A, et al. 2016. Sci Rep. 6: 33847. PubMed
  127. Kumai T, et al. 2015. Sci Rep. 5:16280. PubMed
  128. Polak R, et al. 2015. Blood. 126: 2404 - 2414. PubMed
  129. Hafez A, et al. 2017. Oncogenesis. 10.1038/oncsis.2017.46. PubMed
  130. Putheti P, et al. 2010. PLoS One. 5:e8706. PubMed
  131. Nastasi C, et al. 2021. Sci Rep. 11:1458. PubMed
  132. Molinar-Inglis O, et al. 2021. Proc Natl Acad Sci U S A. 118:. PubMed
  133. Erdogan M, et al. 2022. Chem Biodivers. 19:e202200659. PubMed
  134. Galski H, et al. 2013. Biochem Pharmacol. 86:584. PubMed
  135. Tsou W, et al. 2014. J Biol Chem. 289:25750. PubMed
  136. Dhoonmoon A, et al. 2020. Nucleic Acids Res. 48:7252. PubMed
  137. Gladow N, et al. 2020. PLoS One. 15:e0227734. PubMed
  138. Lee HW, et al. 2018. Am J Physiol Renal Physiol. 314:F280. PubMed
  139. Ki H, et al. 2017. Biomed Pharmacother. 10.1016/j.biopha.2017.09.118. PubMed
  140. Shadboorestan A, et al. 2022. Iran J Basic Med Sci. 25:506. PubMed
  141. Huang Y, et al. 2022. Front Cell Dev Biol. 9:837777. PubMed
  142. Babaei A, et al. 2020. Daru. 28:555. PubMed
  143. King R, et al. 2021. Sci Adv. 7:eabj5293. PubMed
  144. Cai Z, et al. 2020. Cell Rep. 31:107816. PubMed
  145. Liu B, et al. 2016. J Biol Chem. 291: 23869 - 23881. PubMed
  146. Lhuillier C, et al. 2015. J Biol Chem. 290: 16797 - 16811. PubMed
  147. Passaro C, et al. 2013. Endocr Relat Cancer. 20:633. PubMed
  148. Mulik R, et al. 2010. Int J Pharm. 398:190. PubMed
  149. Speth C, et al. 2013. J Infect Dis. 207:823. PubMed
  150. Schuler F, et al. 2017. Nat Commun. . 10.1038/s41467-017-01850-4. PubMed
  151. Di Somma S, et al. 2019. Cancers (Basel). 1.70625. PubMed
  152. Abu El Maaty MA, et al. 2021. Sci Adv. 7: . PubMed
  153. Bahl S, et al. 2021. Cell Death Dis. 12:469. PubMed
  154. Jackson LM, et al. 2021. Nucleic Acids Res. 49:12855. PubMed
  155. Lin W, et al. 2014. PLoS One. 9:83160. PubMed
  156. Zhang X, et al. 2014. Acta Biochim Biophys Sin. 46:261. PubMed
  157. CO L, et al. 2015. Nat Commun. 6: 7739. PubMed
  158. Huang YL, et al. 2020. Elife. 9:00. PubMed
  159. Labi V, et al. 2019. Genes Dev. 33:1673. PubMed
  160. Fang P, et al. 2019. Commun Biol. 0.315972222. PubMed
  161. Kumar S, et al. 2019. Int J Cancer. 146:1652. PubMed
  162. Zhao CC, et al. 2018. Oncol Rep. 40:3392. PubMed
  163. Schleicher EM, et al. 2018. Nucleic Acids Res. 46:8908. PubMed
  164. Thomas A, et al. 2017. PLoS One.. 10.1371/journal.pone.0183542. PubMed
  165. Tatangelo V, et al. 2022. Front Oncol. 12:877495. PubMed
  166. Alcon C, et al. 2021. Cells. 10:. PubMed
  167. Cao H, et al. 2021. Nat Commun. 12:1792. PubMed
  168. Faria M, et al. 2017. PLoS One. 12(2):e0172689. PubMed
  169. Jones P, et al. 2016. J Biol Chem. 291: 16318 - 16327. PubMed
  170. Awojoodu A, et al. 2014. Blood. 124:1941. PubMed
  171. Intemann J, et al. 2014. Cell Signal. 26:1567. PubMed
  172. Clements KE, et al. 2018. Nucleic Acids Res. 46:8898. PubMed
  173. Bostanabad SY, et al. 2021. Sci Rep. 11:1539. PubMed
  174. Monzen S, et al. 2022. Mol Clin Oncol. 16:19. PubMed
  175. Konda P, et al. 2022. Am J Cancer Res. 12:210. PubMed
  176. Wu J, et al. 2021. Adv Sci (Weinh). 8:e2101029. PubMed
  177. Mendès C, et al. 2019. Sci Rep. 9:14107. PubMed
  178. Lopes–Coelho F, et al. 2017. Oncotarget. 8:82803. PubMed
  179. Lu Y, et al. 2018. Cancer Cell. 33:1048. PubMed
  180. Thanuthanakhun N, et al. 2017. PLoS One. . 10.1371/journal.pone.0187610. PubMed
  181. Kuntz E, et al. 2017. Nat Med. 10.1038/nm.4399. PubMed
  182. Tu Z, et al. 2022. Cell Rep. 40:111072. PubMed
  183. Bensberg M, et al. 2021. Proc Natl Acad Sci U S A. 118:. PubMed
  184. Paparella AS, et al. 2021. Nat Commun. 12:6285. PubMed
  185. Huang YL, et al. 2021. iScience. 24:103168. PubMed
  186. Zhang Y, et al. 2021. Cell Death Dis. 0.563194444. PubMed
  187. Kang JH, et al. 2020. Cell Death Dis. 0.803472222. PubMed
  188. Dewdney B, et al. 2020. Sci Rep. 10:16769. PubMed
  189. Simoni L, et al. 2020. Cell Rep. 33:108330. PubMed
  190. Coutaz M, et al. 2016. Sci Rep. 6:39117. PubMed
  191. Akane K, et al. 2016. Proc Natl Acad Sci U S A. 113: 2460 - 2465. PubMed
  192. Xiong R, et al. 2014. Toxicol Appl Pharmacol. 280:285. PubMed
  193. Chen Y, et al. 2013. J Exp Med. 210:2515. PubMed
  194. Siddhartha V, et al. 2017. Artif Cells Nanomed Biotechnol . 10.1080/21691401.2017.1313267. PubMed
  195. He J, et al. 2017. FASEB J. 31:2893. PubMed
  196. Lyu X, et al. 2019. BMC Genomics. 1.235416667. PubMed
  197. Jing Y, et al. 2019. J Allergy Clin Immunol. 144:1377. PubMed
  198. Quan M, et al. 2019. Oncol Rep. 41:3051. PubMed
  199. Kasikara C, et al. 2021. J Clin Invest. 131:. PubMed
  200. Ning N, et al. 2022. Theranostics. 12:5537. PubMed
  201. Bottardi S, et al. 2020. Exp Hematol. 68:88. PubMed
  202. Young MM, et al. 2019. Cell Death Dis. 1.004861111. PubMed
  203. Santos I, et al. 2019. Nutrients. 2.210416667. PubMed
  204. Vancsik T, et al. 2019. Cancer Med. 3.313888889. PubMed
  205. Zheng M, et al. 2019. Proc Natl Acad Sci U S A. 116:12422. PubMed
  206. Zheng Q, et al. 2017. Mol Oncol. 10.1002/1878-0261.12056. PubMed
  207. Wang Y, et al. 2022. Front Cardiovasc Med. 9:876087. PubMed
  208. Shankman LS, et al. 2021. Curr Biol. 31:2469. PubMed
  209. Du Z, et al. 2020. J Allergy Clin Immunol. . PubMed
  210. Pahari S, et al. 2020. Autophagy. 1.375694444. PubMed
  211. Schleicher EM, et al. 2020. PLoS Genet. 16:e1009176. PubMed
  212. Langsch S, et al. 2016. Cancer Res . 76: 4160 - 4169. PubMed
  213. Xiong R, et al. 2015. Mol Pharmacol. 88: 1045 - 1054. PubMed
  214. Hellmann J, et al. 2013. J Immunol. 191:1383. PubMed
  215. Juel H, et al. 2013. PLoS One. 8:64619. PubMed
  216. Gill K, et al. 2013. Biochim Biophys Acta. 1830:2763. PubMed
RRID
AB_2561291 (BioLegend Cat. No. 640905)
AB_2561292 (BioLegend Cat. No. 640906)
AB_2629519 (BioLegend Cat. No. 640945)

Antigen Details

Biology Area
Apoptosis/Tumor Suppressors/Cell Death, Cell Biology, Neuroscience
Gene ID
308 View all products for this Gene ID
UniProt
View information about Annexin V on UniProt.org

Related FAQs

How is your Annexin made and what sequence does it cover?

It is made in E. coli, covering human aa Met1-Asp320.

How does pH and staining temperature affect Annexin V-Phosphatidylserine binding?

Annexin-Phosphatidylserine binding is lost below pH 5.2 and with prolonged incubation over a temperature of 42°C.

Why do I need to use Annexin V Binding Buffer?

Annexin V binding requires the presence of calcium in the solution.  So, we provide Annexin V Binding Buffer (cat # 422201), which is optimized for the best performance of Annexin V staining.

Can I use RPMI during Annexin V staining?

It is best to follow protocol as described on the product data sheet. Moreover, RPMI 1640 has a relatively high concentration of phosphate and low calcium ion concentration, which negatively impacts Annexin binding to its target phosphatidylserine (PS). Measurement of cell death by using Annexin V may also be significantly affected by time of incubation on ice, calcium concentration, and type of medium.

Can I freeze Annexin V conjugates?

It should not be frozen as it will lead to loss of biological activity due to dimerization.

Is Annexin V suitable for conjugation with the Maxpar® kit for CyTOF®?

Maxpar® Labeling kits require the protein to be partially reduced, so the metal chelate can be introduced through an SH group in the hinge region of the reduced antibody. Human Annexin V contains only one Cysteine which was reported to be chemically inactive. Thus, the Maxpar® labeling protocol would not work with Annexin V, unless a free –SH group can be introduced to Annexin V.  For more information regarding SH-mediated conjugation of Annexin V please consult published papers such as this one.

Go To Top Version: 6    Revision Date: 11/01/2023

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere

Login / Register
Remember me
Forgot your password? Reset password?
Create an Account